These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27217433)

  • 1. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries.
    Wirtz VJ; Kaplan WA; Kwan GF; Laing RO
    Circulation; 2016 May; 133(21):2076-85. PubMed ID: 27217433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
    Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
    J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
    Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
    Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal.
    Sharma A; Kaplan WA; Satheesh G; Poudyal IP; Gyawali P; Neupane D; Bhandari PM; Malla M; Sapkota S; Mishra SR
    Glob Heart; 2021 May; 16(1):38. PubMed ID: 34040951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
    Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
    BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensuring Patient-Centered Access to Cardiovascular Disease Medicines in Low-Income and Middle-Income Countries Through Health-System Strengthening.
    Tran DN; Njuguna B; Mercer T; Manji I; Fischer L; Lieberman M; Pastakia SD
    Cardiol Clin; 2017 Feb; 35(1):125-134. PubMed ID: 27886782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries.
    Kishore SP; Vedanthan R; Fuster V
    J Am Coll Cardiol; 2011 May; 57(20):1980-7. PubMed ID: 21565635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon.
    Jingi AM; Noubiap JJ; Ewane Onana A; Nansseu JR; Wang B; Kingue S; Kengne AP
    PLoS One; 2014; 9(11):e111812. PubMed ID: 25369455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to cardiovascular medicines in low- and middle-income countries: a mini review.
    Harrison MA; Marfo AFA; Annan A; Ankrah DNA
    Glob Health Res Policy; 2023 May; 8(1):17. PubMed ID: 37221559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between essential medicines and health outcomes for cardiovascular disease.
    Steiner L; Fraser S; Maraj D; Persaud N
    BMC Cardiovasc Disord; 2021 Mar; 21(1):151. PubMed ID: 33765933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study.
    Dzudie A; Njume E; Abanda M; Aminde L; Hamadou B; Dzekem B; Azabji M; Doualla MS; Ngowe M; Kengne AP
    PLoS One; 2020; 15(3):e0229307. PubMed ID: 32130252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
    Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
    Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study.
    Kibirige D; Atuhe D; Kampiire L; Kiggundu DS; Donggo P; Nabbaale J; Mwebaze RM; Kalyesubula R; Lumu W
    Int J Equity Health; 2017 Aug; 16(1):154. PubMed ID: 28836972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data.
    van Mourik MS; Cameron A; Ewen M; Laing RO
    BMC Cardiovasc Disord; 2010 Jun; 10():25. PubMed ID: 20534118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping actions to improve access to medicines for mental disorders in low and middle income countries.
    Barbui C; Dua T; Kolappa K; Saraceno B; Saxena S
    Epidemiol Psychiatr Sci; 2017 Oct; 26(5):481-490. PubMed ID: 28067194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
    Ewen M; Zweekhorst M; Regeer B; Laing R
    PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
    Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
    BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world.
    Niëns LM; Cameron A; Van de Poel E; Ewen M; Brouwer WB; Laing R
    PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20824175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.
    Mendis S; Fukino K; Cameron A; Laing R; Filipe A; Khatib O; Leowski J; Ewen M
    Bull World Health Organ; 2007 Apr; 85(4):279-88. PubMed ID: 17546309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.